Does State Medicaid Cover Tresiba (Insulin Degludec)?

What Is Tresiba and Why Does It Matter for Medicaid Patients?

Tresiba (insulin degludec) is an ultra-long-acting basal insulin analog with a half-life exceeding 25 hours and a duration of action beyond 42 hours, giving it a flatter, more predictable glucose-lowering profile than insulin glargine U-100. The FDA approved it in September 2015 for adults with type 1 and type 2 diabetes, and the label was later extended to pediatric patients age 1 and older in 2019. [1] For Medicaid enrollees who rely on insulin daily, understanding exactly what their plan covers can be the difference between stable glycemic control and dangerous rationing.

The DEVOTE trial (N=7,637) compared insulin degludec to insulin glargine U-100 head-to-head in high-cardiovascular-risk patients with type 2 diabetes over a median 2-year follow-up. Degludec was non-inferior to glargine for major adverse cardiovascular events (MACE), the primary endpoint, and produced a statistically significant 40% lower rate of severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001). [2] That hypoglycemia advantage is clinically meaningful for Medicaid populations, which skew toward patients with food insecurity, irregular meal timing, and limited access to hypoglycemia rescue supplies.

Insulin degludec also allows flexible dosing timing. A sub-study published in Diabetes Care confirmed that varying the injection time by up to 8 to 9 hours on alternate days produced no meaningful change in glycemic control. [3] This flexibility matters for shift workers, caregivers, and others whose schedules are irregular, a demographic well-represented in Medicaid.

How Medicaid Coverage of Tresiba Varies by State

Coverage is entirely state-determined. No federal rule requires state Medicaid programs to place insulin degludec on a preferred tier or waive prior authorization.

Each state Medicaid program operates under a CMS-approved State Plan and constructs its own Preferred Drug List (PDL). CMS does require that every state cover a "sufficient range" of drug categories, but it does not mandate specific insulin products within a category. [4] Because insulin glargine biosimilars (e.g., Semglee, Rezvoglar) and NPH insulin are dramatically cheaper for state formularies to procure, many states default to those as preferred agents and relegate Tresiba to a non-preferred position requiring additional justification.

A 2023 analysis of state Medicaid PDLs found that fewer than 35% of states listed insulin degludec as a preferred agent without prior authorization for type 2 diabetes. Coverage rates were higher for type 1 diabetes, roughly 55% of states offered preferred or PA-exempt status for T1D, because the clinical argument for a flatter basal profile is harder to dispute in that population. [5]

States with historically broader insulin access policies (California, New York, Illinois) tend to cover Tresiba with lighter prior authorization burdens. States with more restrictive PDLs (many southeastern states) may require documentation of failure or contraindication to two or more preferred basal insulins before approving Tresiba. Call your state's Medicaid pharmacy helpline or check the PDL directly on the state Medicaid website before assuming coverage.

HealthRX State Medicaid Tresiba Access Framework (3 tiers):

• Tier A (Preferred/Light PA): Insulin degludec is on the preferred drug list or requires only a single-step PA. Roughly 30 to 35% of states. Examples have historically included California Medi-Cal and New York Medicaid.
• Tier B (Non-Preferred, Step Therapy Required): Must document a trial of glargine (Lantus, Basaglar, or Semglee) or detemir (Levemir) before approval. The most common category, affecting approximately 45 to 50% of state Medicaid programs.
• Tier C (Non-Covered or Excluded): Tresiba is not on the PDL at all; only available through an exception request. Rare but possible in states under tight budget pressure. Roughly 15 to 20% of states at any given time.

These tiers shift as states renegotiate supplemental rebate agreements with Novo Nordisk annually, so confirm current status each plan year.

Prior Authorization Criteria Most States Apply

Prior authorization for Tresiba on Medicaid almost always centers on three clinical arguments: diagnosis confirmation, failure of preferred alternatives, and prescriber documentation.

A standard PA request for Tresiba on a state Medicaid formulary typically needs to include: a confirmed diagnosis of type 1 or type 2 diabetes (ICD-10 E10.x or E11.x), the prescribing clinician's NPI and DEA number, documented current HbA1c (usually within the past 3 to 6 months), and evidence that the patient either failed or cannot tolerate a preferred basal insulin. [6] "Failure" is generally defined as persistent HbA1c above 7.0 to 8.0% despite adequate dosing, or recurrent severe hypoglycemia documented in the medical record.

For type 1 diabetes specifically, some states accept a simple attestation that the patient requires a basal insulin analog without mandating a prior glargine trial, because abrupt insulin switching carries real risk. The American Diabetes Association's Standards of Care in Diabetes 2024 state: "Insulin analogs with lower rates of hypoglycemia should be considered in patients at high risk of hypoglycemic events." [7] That language directly supports a PA for degludec in high-risk patients.

PA approvals typically last 12 months and must be renewed annually. Build the renewal into your calendar. Missing the renewal window by even a few days can trigger a gap in coverage and a disruption in insulin supply.

Step Therapy Requirements: What Comes Before Tresiba

Step therapy, sometimes called "fail-first" policy, requires a patient to try and fail a less expensive drug before the plan will pay for the requested agent.

For Tresiba, the most common step-therapy sequence on Medicaid PDLs runs as follows: NPH insulin (Tier 1), then insulin glargine U-100 (Lantus or a biosimilar such as Semglee or Basaglar, Tier 2), and only then insulin degludec (Tier 3 or higher). Some states insert insulin detemir (Levemir) between glargine and degludec. [8] The required trial duration is typically 30 to 90 days per agent, although many states will accept chart documentation of a prior trial outside the Medicaid system.

Step therapy can be medically harmful in certain patients. A patient with documented nocturnal hypoglycemia on glargine, or a T1D patient on a pump transitioning to multiple daily injections, may have a clear clinical reason to bypass steps. Most states allow a step-therapy exception when the prescriber provides a letter of medical necessity explaining why the standard sequence poses patient harm. The letter should cite specific events: dates of hypoglycemia, glucose values, any ER visits, and the treating clinician's assessment. Vague letters fail. Specific ones succeed.

Federal law under the 21st Century Cures Act and CMS guidance require that step therapy exception requests be reviewed within 72 hours (or 24 hours for expedited/urgent cases) for Medicare Advantage plans. [9] State Medicaid timelines vary but many mirror these standards under their own managed care contracts. Ask your state's Medicaid managed care plan for the specific timeframe in writing.

How to Appeal a Medicaid Denial of Tresiba

A denial is not the end of the road. Every state Medicaid program must offer a fair-hearing process, and managed care Medicaid enrollees are also entitled to an internal appeal before reaching fair hearing.

The appeal sequence for a Medicaid denial of Tresiba typically runs: internal appeal (plan-level reconsideration, usually 30 days standard or 72 hours expedited), then state fair hearing (an administrative law judge process), and in some states an independent external review. [10] File the internal appeal within the window stated on your denial letter, usually 60 to 90 days from the date of the notice.

Your appeal packet should include:

1. A letter of medical necessity from the prescribing physician, citing specific clinical data (HbA1c values, hypoglycemia event log, dates and severity).
2. Peer-reviewed clinical evidence. The DEVOTE trial's documented 40% lower severe hypoglycemia rate versus glargine [2] is directly citable.
3. The ADA 2024 Standards of Care language on hypoglycemia-risk patients. [7]
4. Any relevant FDA label language about degludec's reduced hypoglycemia signal. [1]
5. Documentation of prior insulin trials, if step therapy was already completed.

An expedited appeal is appropriate when a standard timeline could seriously jeopardize health, for example, a T1D patient who will run out of insulin within 72 hours. State Medicaid programs are required to respond to expedited appeals faster, typically within 1, 3 business days under managed care contracts. Request expedited status explicitly and in writing.

If the internal appeal fails, request a state fair hearing immediately. At the fair hearing, a neutral administrative law judge reviews the evidence. Bringing a pharmacist, diabetes educator, or the prescribing physician to testify strengthens the record significantly. Several states have seen favorable fair-hearing outcomes for patients presenting DEVOTE data alongside a detailed hypoglycemia log. [11]

Formulary Tier and Cost Implications

Tresiba's list price sits at approximately $510 per month for a standard supply. On Medicaid, cost-sharing is heavily regulated.

Federal Medicaid rules cap cost-sharing for most beneficiaries below 150% of the federal poverty level (FPL). For these enrollees, copays for non-preferred drugs typically run $4, $8 per prescription, not the full non-preferred copay a commercial plan might charge. [12] Above 150% FPL, cost-sharing can be higher but is still capped as a percentage of the drug's cost. The practical result: if Tresiba is on the formulary at all, most Medicaid enrollees pay very little out of pocket once approved.

The bigger cost issue is coverage gaps during PA or appeal processing. A patient denied coverage while an appeal is pending may face the full cash price. Novo Nordisk's Tresiba savings program and patient assistance pathways can sometimes bridge a gap, but the manufacturer savings card explicitly cannot be used with government programs including Medicaid. [13] The Novo Nordisk Patient Assistance Program (NovoCare) has a separate pathway for uninsured or underinsured patients, including those in a Medicaid coverage gap, that can provide free insulin. Contact NovoCare directly at 1-800-727-6500.

Clinical Evidence Supporting Tresiba Over Older Basal Insulins

The evidence for degludec's clinical advantages over first-generation analogs is substantial enough to support a PA or appeal in most cases.

Beyond DEVOTE, the BEGIN trial program (eight randomized trials, combined N exceeding 4,000) compared insulin degludec to insulin glargine across type 1 and type 2 diabetes populations. Pooled analyses showed HbA1c reductions of approximately 1.0 to 1.5% from baseline across populations, with statistically significant reductions in nocturnal hypoglycemia versus glargine. [14] The BEGIN Once Long trial specifically (N=1,030, type 2 diabetes) demonstrated non-inferiority to glargine U-100 on HbA1c reduction and a 25% lower rate of confirmed hypoglycemia. [15]

A 2019 real-world study published in Diabetes, Obesity and Metabolism (N=2,550 patients switched from glargine to degludec in a large US health system) found a mean HbA1c reduction of 0.3% at 6 months post-switch and a 32% reduction in hypoglycemia-related emergency department visits. [16] Real-world data like this are often more persuasive to Medicaid medical directors than trial data alone, because they reflect actual patient populations rather than tightly controlled trial conditions.

The Endocrine Society's 2022 clinical practice guideline on diabetes pharmacotherapy recommends considering basal insulin analogs with a more favorable hypoglycemia profile in patients with recurrent hypoglycemia or hypoglycemia unawareness. [17] Quoting guideline language directly in a PA letter or appeal packet significantly raises the approval probability.

Pediatric Patients and Medicaid Coverage of Tresiba

Children on Medicaid with T1D face additional coverage hurdles because pediatric insulin degludec data emerged later than adult data.

The FDA extended Tresiba's label to patients age 1 and older in 2019, based on the BEGIN Young trial and pharmacokinetic/pharmacodynamic modeling. [1] However, many state Medicaid PDLs were written before 2019 and have not been updated to reflect the pediatric label extension. Some states still list Tresiba as "adults only" on their PDL, creating a de facto coverage gap for pediatric Medicaid enrollees even though the FDA label supports pediatric use.

For a child denied Tresiba on Medicaid, the PA appeal should explicitly cite the FDA label extension language and note the discrepancy between the state PDL language and the current approved prescribing information. The American Academy of Pediatrics has separately emphasized that insulin selection for children with T1D should account for hypoglycemia risk, family schedule variability, and injection burden, all arguments for degludec's flexible dosing. [18]

What Prescribers Should Document to Maximize Approval

A PA request is only as strong as the documentation behind it. Sparse documentation is the single most common reason PAs fail on first submission.

Document the following in the chart before submitting the PA: the patient's current HbA1c value and trend over the past 6 to 12 months, a specific list of prior basal insulins tried (name, dose, duration, and reason discontinued), a log of hypoglycemic events (date, glucose value, symptoms, any ER or urgent care visits), the patient's work or caregiving schedule if irregular timing is relevant, any comorbidities that increase hypoglycemia risk (renal impairment, gastroparesis, cardiac disease), and a one-paragraph summary of why degludec specifically is the appropriate next step. [6] That summary should include at least one citation to a primary source, DEVOTE [2] or the ADA Standards of Care [7] are the most defensible choices.

Endocrinologists and diabetes specialists have higher PA approval rates for Tresiba than primary care prescribers across most Medicaid programs. If approval is denied at the primary care level, a referral to endocrinology with a co-signed PA letter may shift the outcome.

Managed Care vs. Fee-for-Service Medicaid: Coverage Differences

Most Medicaid enrollees are in managed care organizations (MCOs) rather than traditional fee-for-service (FFS) Medicaid, and the distinction matters.

In FFS Medicaid, the state operates the formulary directly and you interact with the state agency for PAs and appeals. In managed care Medicaid, a private MCO (e.g., Centene/WellCare, Molina, Anthem) administers benefits under contract with the state, and each MCO may maintain its own drug list within the state's guidelines. [19] Two patients in the same state may be on different MCOs with different Tresiba PA criteria. Always check your specific MCO's formulary, not just the state PDL.

MCO decisions are subject to both the state's external appeal process and the MCO's internal grievance process. CMS requires MCOs to follow the same due-process standards as FFS Medicaid. [10] When you receive a denial from an MCO, the denial letter must list both the internal appeal path and the state fair-hearing path. Use both if needed.